Aviva Holdings’s MacroGenics MGNX Stock Holding History

Aviva Holdings’s Portfolio MGNX Stock Details MGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-3,815	Closed	-$48K	–	7
2018 Q4	$48K	Sell	3,815 -660,970	-99%	-$11.1M	0.02%	7
2018 Q3	$14.3M	Sell	664,785 -312,641	-32%	-$6.66M	3.8%	5
2018 Q2	$20.2M	Hold	977,426	–	–	3.28%	5
2018 Q1	$24.6M	Buy	977,426 +190,166	+24%	+$4.62M	9.98%	3
2017 Q4	$15M	Buy	787,260 +671,346	+579%	+$12.5M	8.76%	3
2017 Q3	$2.14M	Buy	+115,914	New	+$2.01M	1.11%	4

Other funds holding MGNX

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

HRCM

Hood River Capital Management Palm Beach Gardens, Florida $13.8B AUM 163.97% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Aviva Holdings's MGNX Position: Q1 2019 in Review

Aviva Holdings sold out of MacroGenics (MGNX) in Q1 2019, closing a stake of 3,815 shares — an estimated $48K sold.

Aviva Holdings first reported a position in MGNX in Q3 2017 and held it in 6 quarters. The position peaked at $24.6M in Q1 2018. 157 funds tracked by Wall St. Rank hold MGNX as of Q1 2019.

Aviva Holdings reported no remaining MacroGenics position as of Q1 2019 after selling out during the quarter.
Aviva Holdings sold 3,815 MacroGenics shares in Q1 2019, an estimated $48K.
Aviva Holdings first reported a position in MacroGenics in Q3 2017 and held it in 6 quarters.
Aviva Holdings's MacroGenics position peaked at $24.6M in Q1 2018.
157 funds tracked by Wall St. Rank held MacroGenics as of Q1 2019.

Based on Aviva Holdings's 13F filing for Q1 2019, filed 15 May 2019.